Velocity Clinical Research’s site in Lublin, Poland, originally founded as KO-MED and acquired by Velocity in 2024, has been operational since 2014. The site boasts a robust patient database of nearly 8,000 individuals and offers comprehensive facilities, including three doctor’s offices, a treatment room, and a laboratory. With access to specialized diagnostic equipment such as X-rays, ultrasounds, MRIs, and spirometry located within the hospital, the site provides advanced medical capabilities. Over 50 doctors have collaborated with the center, and it currently maintains direct cooperation with 30 specialists across various fields, including rheumatology, internal medicine, dermatology, cardiology, and oncology.
The Lublin team is experienced in conducting Phase II, III, and IV clinical trials, with previous experience in Phase I studies. By cultivating strong relationships with the local community and leveraging its extensive expertise, the Lublin site ensures fast and accurate patient enrollment, while maintaining a commitment to compassionate, high-quality patient care and advancing medical research.
Jetzt in Lublin einschreiben
Velocity nimmt Teilnehmer für klinische Studien in Lublin zu den folgenden Erkrankungen auf:
- Vorhofflimmern (AFib)
- Herz-Kreislauf-Risiko bei übergewichtigen Personen
- Chronische Rhinosinusitis
- Diabetes
- Endometriose
- Hypercholesterinämie (hoher Cholesterinspiegel)
- Hypertonie (Bluthochdruck)
- Hals- und Kopfkrebs
- Psoriatische Arthritis
- RSV-Impfstoff
